139889-53-5 Usage
Type
Chemical compound.
Therapeutic potential
Yes, with potential applications in pharmacology and medicinal chemistry.
Function
Selective inhibitor of sphingolipid biosynthesis.
Specific target
Ceramide synthase.
Impact on cell signaling
Disrupts the production of ceramide, a lipid molecule involved in cell signaling and apoptosis.
Anti-cancer properties
Yes, PPMP has been studied for its potential in disrupting ceramide production, which can lead to cell death in cancer cells.
Investigation for genetic disorders and neurodegenerative diseases
Yes, PPMP has been researched for its potential in treating certain genetic disorders and neurodegenerative diseases due to its effects on sphingolipid biosynthesis.
Check Digit Verification of cas no
The CAS Registry Mumber 139889-53-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,9,8,8 and 9 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 139889-53:
(8*1)+(7*3)+(6*9)+(5*8)+(4*8)+(3*9)+(2*5)+(1*3)=195
195 % 10 = 5
So 139889-53-5 is a valid CAS Registry Number.
139889-53-5Relevant articles and documents
2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS
-
Page/Page column 94, (2010/04/27)
A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof
